Correspondence
Deep Venous Thrombosis and Thalidomide Therapy for Multiple Myeloma
N Engl J Med 2001; 344:1951-1952June 21, 2001
- Article
To the Editor:
Thalidomide is effective for the treatment of refractory myeloma.1 Its role in the initial treatment of the disease is under active investigation.2,3 We report the occurrence of deep venous thrombosis with the use of thalidomide in combination with other active agents in patients with newly diagnosed myeloma.
We initiated a phase 2 trial of treatment with thalidomide, doxorubicin, and dexamethasone in previously untreated patients with symptomatic stage 2 or 3 myeloma at the Memorial Sloan-Kettering Cancer Center. The trial was supported by Celgene, which manufactures thalidomide. Thalidomide was administered orally at a dose of 100 mg for 2 weeks, and the dose was then increased to 200 mg; doxorubicin (36 mg per square meter of body-surface area) was administered as an intravenous bolus on the first day of each 28-day cycle, and dexamethasone (40 mg per day) was given daily on days 1 through 4, 9 through 12, and 17 through 20 of each cycle. We planned a total of four cycles of therapy with this regimen. As of February 2001, we had enrolled 15 patients, and symptomatic deep venous thrombosis had developed in 4 of the 15 (27 percent). The incidence of deep venous thrombosis was much higher than we had previously noted in the treatment of patients with newly diagnosed myeloma, and therefore, in February 2001, the trial was suspended. At that time, five patients could be evaluated, all of whom had responses to the study regimen. One had a complete response, three had very good partial responses, and one had a partial response.
A separate phase 2 trial of thalidomide and dexamethasone for the treatment of patients with newly diagnosed myeloma is ongoing at the Mayo Clinic. As of February 2001, 45 patients had been enrolled in the study, and 3 (7 percent) had had thrombotic events. Two patients had documented deep venous thrombosis; acute dyspnea developed in the third patient, who died within an hour in a hospital emergency room, with a clinical diagnosis of pulmonary embolism.
Arterial thrombosis and venous thrombosis after thalidomide therapy have been reported in a case series of five patients: four with lupus erythematosus and one with severe atopic dermatitis.4 Thalidomide is an effective and important agent in the treatment of myeloma. Given the frequency of thrombotic events, however, we do not recommend combining thalidomide with other chemotherapeutic agents in patients with newly diagnosed myeloma outside of approved clinical trials. A safe dose and schedule of administration should be established, and a clearer understanding of the thrombophilia obtained.
4 ReferencesKeren Osman, M.D.
Raymond Comenzo, M.D.
Memorial Sloan-Kettering Cancer Center, New York, NY 10021S. Vincent Rajkumar, M.D.
Mayo Clinic, Rochester, MN 559051
Singhal S ,Mehta J ,Desikan R , et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571
Full Text | Web of Science | Medline2
Rajkumar SV ,Gertz MA ,Witzig TE . Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N Engl J Med 2000;343:972-973
Full Text | Web of Science | Medline3
Rajkumar SV ,Hayman S ,Fonseca R , et al. Thalidomide plus dexamethasone (Thal/Dex) and thalidomide alone (Thal) as first line therapy for newly diagnosed myeloma (MM). Blood 2000;96:Part 1:168a-168a abstract.
Web of Science4
Flageul B ,Wallach D ,Cavelier-Balloy B ,Bechelez H ,Carsuzaa F ,Dubertret L . Thalidomide and thrombosis. Ann Dermatol Venereol 2000;127:171-174
Web of Science | Medline
- Citing Articles (81)
Citing Articles
1
Satadal Chatterjee, Shobhan Gaddameedhi. 2011. In-Depth Look: Anti-TNF-α Therapies. .
CrossRef2
Asuka Hoshi, Aya Matsumoto, Jihwa Chung, Yu Isozumi, Takatoshi Koyama. (2011) Activation of coagulation by a thalidomide-based regimen. Blood Coagulation & Fibrinolysis 22:6, 532-540
CrossRef3
Benedetto Bruno, Francesca Gay, Mario Boccadoro, Antonio Palumbo. (2011) Management of Myeloma: An Italian Perspective. Clinical Lymphoma Myeloma and Leukemia 11, S82-S86
CrossRef4
Niels W.C.J. van de Donk, Henk M. Lokhorst, Meletios Dimopoulos, Michele Cavo, Gareth Morgan, Hermann Einsele, Martin Kropff, Steve Schey, Hervé Avet-Loiseau, Heinz Ludwig, Hartmut Goldschmidt, Pieter Sonneveld, Hans E. Johnsen, Joan Bladé, Jesús F. San-Miguel, Antonio Palumbo. (2011) Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treatment Reviews 37:4, 266-283
CrossRef5
M. CARRIER, G. LE GAL, J. TAY, C. WU, A. Y. LEE. (2011) Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis 9:4, 653-663
CrossRef6
Sigurdur Yngvi Kristinsson, Magnus Björkholm, Sam Schulman, Ola Landgren. (2011) Hypercoagulability in Multiple Myeloma and Its Precursor State, Monoclonal Gammopathy of Undetermined Significance. Seminars in Hematology 48:1, 46-54
CrossRef7
Bo H. Chao, Lisa Lepeak, Ticiana Leal, H. Ian Robins. (2011) Clinical Use of the Low-Molecular-Weight Heparins in Cancer Patients: Focus on the Improved Patient Outcomes. Thrombosis 2011, 1-10
CrossRef8
S. Y. Kristinsson. (2010) Thrombosis in Multiple Myeloma. Hematology 2010:1, 437-444
CrossRef9
A. Palumbo, F. Davies, M. Kropff, J. Bladé, M. Delforge, F. Costa, R. Garcia Sanz, S. Schey, T. Facon, G. Morgan, P. Moreau. (2010) Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. Annals of Hematology 89:8, 803-811
CrossRef10
Noppacharn Uaprasert, Peter M. Voorhees, Nigel Mackman, Nigel S. Key. (2010) Venous thromboembolism in multiple myeloma: Current perspectives in pathogenesis. European Journal of Cancer 46:10, 1790-1799
CrossRef11
S. Y. Kristinsson, R. M. Pfeiffer, M. Bjorkholm, L. R. Goldin, S. Schulman, C. Blimark, U.-H. Mellqvist, A. Wahlin, I. Turesson, O. Landgren. (2010) Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood 115:24, 4991-4998
CrossRef12
Joseph R. Carver, Chaitali J. Desai. 2010. Cardiovascular Toxicity of Antitumor Drugs: Dimension of the Problem in Adult Settings. , 127-199.
CrossRef13
Khaled M. Musallam, Fadi S. Dahdaleh, Ali I. Shamseddine, Ali T. Taher. (2009) Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thrombosis Research 123:5, 679-686
CrossRef14
S. Vincent Rajkumar. (2009) Multiple Myeloma. Current Problems in Cancer 33:1, 7-64
CrossRef15
S. Y. Kristinsson, T. R. Fears, G. Gridley, I. Turesson, U.-H. Mellqvist, M. Bjorkholm, O. Landgren. (2008) Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 112:9, 3582-3586
CrossRef16
Sagar Lonial, Paul G Richardson, Jesús San Miguel, Pieter Sonneveld, Michael W Schuster, Joan Bladé, Jamie Cavenagh, S. Vincent Rajkumar, Andrzej J Jakubowiak, Dixie-Lee Esseltine, Kenneth C Anderson, Jean-Luc Harousseau. (2008) Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. British Journal of Haematology 143:2, 222-229
CrossRef17
Adriana M.W. van Marion, Johannes J.A. Auwerda, Ton Lisman, Pieter Sonneveld, M.P.M. de Maat, Henk M. Lokhorst, Frank W.G. Leebeek. (2008) Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leukemia Research 32:7, 1078-1084
CrossRef18
Smitha Patiyil Menon, S. Vincent Rajkumar, Martha Lacy, Patrizia Falco, Antonio Palumbo. (2008) Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer 112:7, 1522-1528
CrossRef19
A Palumbo, S V Rajkumar, M A Dimopoulos, P G Richardson, J San Miguel, B Barlogie, J Harousseau, J A Zonder, M Cavo, M Zangari, M Attal, A Belch, S Knop, D Joshua, O Sezer, H Ludwig, D Vesole, J Bladé, R Kyle, J Westin, D Weber, S Bringhen, R Niesvizky, A Waage, M von Lilienfeld-Toal, S Lonial, G J Morgan, R Z Orlowski, K Shimizu, K C Anderson, M Boccadoro, B G Durie, P Sonneveld, M A Hussein. (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22:2, 414-423
CrossRef20
A. Palumbo, T. Facon, P. Sonneveld, J. Blade, M. Offidani, F. Gay, P. Moreau, A. Waage, A. Spencer, H. Ludwig, M. Boccadoro, J.-L. Harousseau. (2008) Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111:8, 3968-3977
CrossRef21
Ruben Niesvizky, Déborah M. Martínez-Baños. (2008) Aspirin as thromboprophylaxis in myeloma. Leukemia & Lymphoma 49:8, 1646-1647
CrossRef22
Angela Dispenzieri. (2007) Complications of Myeloma Therapy. Hematology/Oncology Clinics of North America 21:6, 1247-1273
CrossRef23
Laura F. Hutchins, James Moon, Joseph I. Clark, John A. Thompson, Marianne K. Lange, Lawrence E. Flaherty, Vernon K. Sondak. (2007) Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. Cancer 110:10, 2269-2275
CrossRef24
Sheeba Thomas, Tiffany Richards, Donna M. Weber. 2007. Novel Agents for Previously Untreated Multiple Myeloma. , 141-168.
CrossRef25
S
bastien Maillard, Elias Fattal, V
CrossRef26
F. Merchionne, F. Perosa, F. Dammacco. (2007) New therapies in multiple myeloma. Clinical and Experimental Medicine 7:3, 83-97
CrossRef27
Hau C. Kwaan, Brian Vicuna. (2007) Thrombosis and bleeding in cancer patients. Oncology Reviews 1:1, 14-27
CrossRef28
Maurizio Zangari, Francesca Elice, Louis Fink, Guido Tricot. (2007) Thrombosis in multiple myeloma. Expert Review of Anticancer Therapy 7:3, 307-315
CrossRef29
Ruben Niesvizky, Déborah Martínez-Baños, Jessica Jalbrzikowski, Paul Christos, Jessica Furst, Maria De Sancho, Tomer Mark, Roger Pearse, Madhu Mazumdar, Faiza Zafar, Karen Pekle, John Leonard, David Jayabalan, Morton Coleman. (2007) Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leukemia & Lymphoma 48:12, 2330-2337
CrossRef30
Frederick R. Rickles, Mark Levine. 2007. Thrombosis and Cancer. , 389-403.
CrossRef31
Susan E. Krown, Donna Niedzwiecki, Wen-Jen Hwu, Lydia Hodgson, Alan N. Houghton, Frank G. Haluska, . (2006) Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain. Cancer 107:8, 1883-1890
CrossRef32
Axel Glasmacher, Corinna Hahn, Florian Hoffmann, Ralph Naumann, Hartmut Goldschmidt, Marie Lilienfeld-Toal, Katjana Orlopp, Ingo Schmidt-Wolf, Marcus Gorschluter. (2006) A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. British Journal of Haematology 132:5, 584-593
CrossRef33
Antonio Palumbo, Sara Bringhen, Tommaso Caravita, Emanuela Merla, Vincenzo Capparella, Vincenzo Callea, Clotilde Cangialosi, Mariella Grasso, Fausto Rossini, Monica Galli, Lucio Catalano, Elena Zamagni, Maria Teresa Petrucci, Valerio De Stefano, Manuela Ceccarelli, Maria Teresa Ambrosini, Ilaria Avonto, Patrizia Falco, Giovannino Ciccone, Anna Marina Liberati, Pellegrino Musto, Mario Boccadoro. (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. The Lancet 367:9513, 825-831
CrossRef34
Ramón García-Sanz. (2006) Thalidomide in multiple myeloma. Expert Opinion on Pharmacotherapy 7:2, 195-213
CrossRef35
John T. Wiernikowski, Uma H. Athale. (2006) Thromboembolic complications in children with cancer. Thrombosis Research 118:1, 137-152
CrossRef36
Klaus Podar, Teru Hideshima, Yu-Tzu Tai, Paul G Richardson, Dharminder Chauhan, Kenneth C Anderson. (2006) Emerging Therapies for Multiple Myeloma. American Journal of Cancer 5:3, 141-153
CrossRef37
Kena C. Miller, Swaminathan Padmanabhan, Laurie Dimicelli, Dawn Depaolo, Beverly Landrigan, Jihnhee Yu, Virginia Doran, Patricia Marshal, Asher Chanan-Khan. (2006) Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leukemia & Lymphoma 47:11, 2339-2343
CrossRef38
Seong-Hoon Jeong, Je-Jung Lee, Sang-Kyun Sohn, Ho-Jin Shin, Deok-Hwan Yang, Yeo-Kyeoung Kim, Sang-Ki Kim, Jin-Ho Baek, Dong-Hwan Kim, Jong-Gwang Kim, Joo-Sep Chung, Goon-Jae Cho, Hyeoung-Joon Kim. (2006) Clinical Efficacy of Thalidomide Containing Regimens as a Primary Therapy in Patients with Multiple Myeloma. The Korean Journal of Hematology 41:2, 83
CrossRef39
Christine S. Halligan, Martha Q. Lacy, S. Vincent Rajkumar, Angela Dispenzieri, Thomas E. Witzig, John A. Lust, Rafael Fonseca, Morie A. Gertz, Robert A. Kyle, Rajiv K. Pruthi. (2006) Natural history of thromboembolism in AL amyloidosis. Amyloid 13:1, 31-36
CrossRef40
Hani Hassoun, Lilian Reich, Virginia M. Klimek, Madhav Dhodapkar, Adam Cohen, Tarun Kewalramani, Rachel Zimman, Lisa Drake, Elyn R. Riedel, Cyrus V. Hedvat, Julie Teruya-Feldstein, Daniel A. Filippa, Martin Fleisher, Stephen D. Nimer, Raymond L. Comenzo. (2006) Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. British Journal of Haematology 132:2, 155-161
CrossRef41
2006. Thalidomide. , 3343-3360.
CrossRef42
Dirk Hönemann, H. Miles Prince. (2006) Myeloma, thalidomide and thrombosis. Leukemia & Lymphoma 47:11, 2273-2275
CrossRef43
S. V. Rajkumar. (2005) Thalidomide Therapy and Deep Venous Thrombosis in Multiple Myeloma. Mayo Clinic Proceedings 80:12, 1549-1551
CrossRef44
S. V. Rajkumar, R. A. Kyle. (2005) Multiple Myeloma: Diagnosis and Treatment. Mayo Clinic Proceedings 80:10, 1371-1382
CrossRef45
Sandy Srinivas, Alice E. Guardino. (2005) A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma. BJU International 96:4, 536-539
CrossRef46
Charalampia Kyriakou, Kirsty Thomson, Shirley D'Sa, Angela Flory, Judith Hanslip, Anthony H. Goldstone, Kwee L. Yong. (2005) Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. British Journal of Haematology 129:6, 763-770
CrossRef47
Yutaka Hattori, Masayuki Shimoda, Shinichiro Okamoto, Toru Satoh, Tsunayuki Kakimoto, Yasuo Ikeda. (2005) Pulmonary hypertension and thalidomide therapy in multiple myeloma. British Journal of Haematology 128:6, 885-887
CrossRef48
Tallal Younis, Philip McCarthy. (2005) Reply to Hattori et al: Thalidomide and pulmonary hypertension. A causal or casual relationship?. British Journal of Haematology 128:6, 887-888
CrossRef49
P. Schutt, P. Ebeling, U. Buttkereit, D. Brandhorst, B. Opalka, M. Hoiczyk, M. Flasshove, J. Hense, P. Bojko, K. Metz, T. Moritz, S. Seeber, M. R. Nowrousian. (2005) Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. European Journal of Haematology 74:1, 40-46
CrossRef50
P. Hausfater, N. Costedoat‐Chalumeau, Z. Amoura, P. Cacoub, T. Papo, G. Grateau, V. Leblond, P. Godeau, J. C. Piette. (2005) AL cardiac amyloidosis and arterial thromboembolic events. Scandinavian Journal of Rheumatology 34:4, 315-319
CrossRef51
Kyle, Robert A., Rajkumar, S. Vincent, . (2004) Multiple Myeloma. New England Journal of Medicine 351:18, 1860-1873
Full Text52
Yutaka Hattori, Toyotaka Iguchi. (2004) Thalidomide for the treatment of multiple myeloma. Congenital Anomalies 44:3, 125-136
CrossRef53
S. V. Rajkumar. (2004) Thalidomide: Tragic Past and Promising Future. Mayo Clinic Proceedings 79:7, 899-903
CrossRef54
Michel Vulfovich, Nabil Saba. (2004) Molecular biological design of novel antineoplastic therapies. Expert Opinion on Investigational Drugs 13:6, 577-607
CrossRef55
Clara Montagut, Francesc Bosch, Luís Villela, Laura Rosiñol, Joan Bladé. (2004) Aminoglycoside-associated Severe Renal Failure in Patients with Multiple Myeloma Treated with Thalidomide. Leukemia & Lymphoma 45:8, 1711-1712
CrossRef56
Martin H. Kropff, Nicola Lang, Guido Bisping, Nicole Domine, Georg Innig, Markus Hentrich, Manfred Mitterer, Thomas Sudhoff, Roland Fenk, Christian Straka, Achim Heinecke, Olaf M. Koch, Helmut Ostermann, Wolfgang E. Berdel, Joachim Kienast. (2003) Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. British Journal of Haematology 122:4, 607-616
CrossRef57
Heinz Gisslinger, Mathias Kees. (2003) Therapy strategies for multiple myeloma: current status. Wiener Klinische Wochenschrift 115:13-14, 451-461
CrossRef58
Massimo Fanelli, Roberta Sarmiento, Domenico Gattuso, Guido Carillio, Barbara Capaccetti, Angelo Vacca, Aldo Maria Roccaro, Giampietro Gasparini. (2003) Thalidomide: a new anticancer drug?. Expert Opinion on Investigational Drugs 12:7, 1211-1225
CrossRef59
M. N. Levine, A. Y. Lee, A. K. Kakkar. (2003) From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. Journal of Thrombosis and Haemostasis 1:7, 1456-1463
CrossRef60
Robert J. Behrens, James L. Gulley, William L. Dahut. (2003) Pulmonary Toxicity During Prostate Cancer Treatment With Docetaxel and Thalidomide. American Journal of Therapeutics 10:3, 228-232
CrossRef61
Tallal Hussein Younis. (2003) Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma. British Journal of Haematology 121:1, 191-192
CrossRef62
M. C. Minnema, R. Fijnheer, P. G. De Groot, H. M. Lokhorst. (2003) Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. Journal of Thrombosis and Haemostasis 1:3, 445-449
CrossRef63
McDonald K. Horne, William D. Figg, Phil Arlen, James Gulley, Catherine Parker, Nehal Lakhani, Howard Parnes, William L. Dahut. (2003) Increased Frequency of Venous Thromboembolism with the Combination of Docetaxel and Thalidomide in Patients with Metastatic Androgen-Independent Prostate Cancer. Pharmacotherapy 23:3, 315-318
CrossRef64
T. Barbui, A. Falanga. (2003) Thalidomide and thrombosis in multiple myeloma. Journal of Thrombosis and Haemostasis 1:3, 421-422
CrossRef65
S.James Matthews, Christopher McCoy. (2003) Thalidomide: A review of approved and investigational uses. Clinical Therapeutics 25:2, 342-395
CrossRef66
Leonard T Heffner, Sagar Lonial. (2003) Breakthroughs in the Management of Multiple Myeloma. Drugs 63:16, 1621-1636
CrossRef67
(2003) Novel therapies for multiple myeloma. British Journal of Haematology 120:1, 10-17
CrossRef68
(2003) Thalidomide in multiple myeloma: current status and future prospects. British Journal of Haematology 120:1, 18-26
CrossRef69
Michelle T Pelle, Victoria P Werth. (2003) Thalidomide in Cutaneous Lupus Erythematosus. American Journal of Clinical Dermatology 4:6, 379-387
CrossRef70
S. Kumar, M. A. Gertz, A. Dispenzieri, M. Q. Lacy, S. M. Geyer, N. L. Iturria, R. Fonseca, S. R. Hayman, J. A. Lust, R. A. Kyle, P. R. Greipp, T. E. Witzig, S. V. Rajkumar. (2003) Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple Myeloma. Mayo Clinic Proceedings 78:1, 34-39
CrossRef71
Apurva A. Desai, Nicholas J. Vogelzang, Brian I. Rini, Rafat Ansari, Stuart Krauss, Walter M. Stadler. (2002) A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 95:8, 1629-1636
CrossRef72
Tsunayuki Kakimoto, Yutaka Hattori, Shinichiro Okamoto, Norihide Sato, Tamihiro Kamata, Masaya Yamaguchi, Kunihiko Morita, Taketo Yamada, Nobuyuki Takayama, Hideo Uchida, Naoki Shimada, Yusuke Tanigawara, Yasuo Ikeda. (2002) Thalidomide for the Treatment of Refractory Multiple Myeloma: Association of Plasma Concentrations of Thalidomide and Angiogenic Growth Factors with Clinical Outcome. Cancer Science 93:9, 1029-1036
CrossRef73
J Gachon, J.J Grob, M.A Richard. (2002) Accidents thrombotiques favorisés par le thalidomide : deux observations. La Revue de Médecine Interne 23:8, 724-727
CrossRef74
S. V. Rajkumar, M. A. Gertz, R. A. Kyle, P. R. Greipp, . (2002) Current Therapy for Multiple Myeloma. Mayo Clinic Proceedings 77:8, 813-822
CrossRef75
Michelle A. Elliott, Ruben A. Mesa, Chin-Yang Li, C. Christopher Hook, Stephen M. Ansell, Ralph M. Levitt, Susan M. Geyer, Ayalew Tefferi. (2002) Thalidomide treatment in myelofibrosis with myeloid metaplasia. British Journal of Haematology 117:2, 288-296
CrossRef76
P Richardson, T Hideshima, K Anderson. (2002) Thalidomide in multiple myeloma. Biomedicine & Pharmacotherapy 56:3, 115-128
CrossRef77
Shaker A Mousa. (2002) Anticoagulants in thrombosis and cancer: the missing link. Expert Review of Anticancer Therapy 2:2, 227-233
CrossRef78
S Singhal, J Mehta. (2002) Thalidomide in cancer. Biomedicine & Pharmacotherapy 56:1, 4-12
CrossRef79
Paul Richardson, Teru Hideshima, Kenneth Anderson. (2002) T
HALIDOMIDE : Emerging Role in Cancer Medicine. Annual Review of Medicine 53:1, 629-657
CrossRef80
&NA;. (2001) DVT halts phase II thalidomide for myeloma trial. Inpharma Weekly &NA;:1294, 21
CrossRef81
&NA;. (2001) DVT halts phase II thalidomide for myeloma trial. Reactions Weekly &NA;:858, 3
CrossRef
